WO2012069150A3 - Cytoprotectant agents for the prevention of drug-associated side-effects - Google Patents

Cytoprotectant agents for the prevention of drug-associated side-effects Download PDF

Info

Publication number
WO2012069150A3
WO2012069150A3 PCT/EP2011/005721 EP2011005721W WO2012069150A3 WO 2012069150 A3 WO2012069150 A3 WO 2012069150A3 EP 2011005721 W EP2011005721 W EP 2011005721W WO 2012069150 A3 WO2012069150 A3 WO 2012069150A3
Authority
WO
WIPO (PCT)
Prior art keywords
cytoprotectant
prevention
drug
agents
effects
Prior art date
Application number
PCT/EP2011/005721
Other languages
French (fr)
Other versions
WO2012069150A2 (en
Inventor
Dominic HÜTZEN
Original Assignee
Powerpore Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powerpore Gmbh filed Critical Powerpore Gmbh
Publication of WO2012069150A2 publication Critical patent/WO2012069150A2/en
Publication of WO2012069150A3 publication Critical patent/WO2012069150A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

The invention relates to cytoprotectant agents as medicaments for the prevention of drug-associated osteonecrosis of the jaw and/or the femur, to pharmaceutical compositions comprising a cytoprotectant agent and a bisphosphonate or denosumab, and to a method for the treatment or prevention of osteoporosis by the concurrent or subsequent adminstration of a cytoprotectant agent and a bisphosphonate or denosumab.
PCT/EP2011/005721 2010-11-22 2011-11-14 Cytoprotectant agents for the prevention of drug-associated side-effects WO2012069150A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10014829 2010-11-22
EP10014829.5 2010-11-22
EP11004058.1 2011-05-17
EP11004058 2011-05-17

Publications (2)

Publication Number Publication Date
WO2012069150A2 WO2012069150A2 (en) 2012-05-31
WO2012069150A3 true WO2012069150A3 (en) 2012-08-16

Family

ID=45401024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/005721 WO2012069150A2 (en) 2010-11-22 2011-11-14 Cytoprotectant agents for the prevention of drug-associated side-effects

Country Status (1)

Country Link
WO (1) WO2012069150A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115040524A (en) * 2022-07-27 2022-09-13 深圳市中西医结合医院 Use of 4-cholesten-3-ones for the treatment of multiple myeloma bone disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186863A1 (en) * 2006-03-31 2009-07-23 Trophos Use of cholest-4-en-3-one derivatives for obtaining a cytoprotective drug
US20090203662A1 (en) * 2005-12-20 2009-08-13 Trophos Novel derivatives of cholest-4-en-3-one oxime, pharmaceutical compositions containing them and preparation method
US20090312434A1 (en) * 2006-03-09 2009-12-17 Trophos Use of 3,5-seco-4-nor-cholestane derivatives for obtaining a cytoprotective drug
EP2233142A1 (en) * 2007-12-10 2010-09-29 Cosmed Pharmaceutical Co., Ltd. Transdermally absorptive preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1601363T3 (en) 2003-03-11 2012-09-03 Trophos Use as a drug of cholest-4-one-3-one derivatives, pharmaceutical compositions containing them and novel derivatives
FR2874923B1 (en) 2004-09-07 2006-10-27 Trophos Sa APPLICATION AS MEDICAMENTS OF 3, 5-SECO-4-NOR-CHOLESTANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, NEW DERIVATIVES AND PROCESS FOR THEIR PREPARATION
FR2887879B1 (en) 2005-07-01 2008-09-26 Trophos Sa NOVEL CHEMICAL COMPOUNDS AND THEIR USES AS MEDICAMENT, ESPECIALLY IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
FR2914188B1 (en) 2007-03-28 2012-06-22 Trophos NEW CHOLEST-4-EN-3-ONE OXIME COMPOSITION

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203662A1 (en) * 2005-12-20 2009-08-13 Trophos Novel derivatives of cholest-4-en-3-one oxime, pharmaceutical compositions containing them and preparation method
US20090312434A1 (en) * 2006-03-09 2009-12-17 Trophos Use of 3,5-seco-4-nor-cholestane derivatives for obtaining a cytoprotective drug
US20090186863A1 (en) * 2006-03-31 2009-07-23 Trophos Use of cholest-4-en-3-one derivatives for obtaining a cytoprotective drug
EP2233142A1 (en) * 2007-12-10 2010-09-29 Cosmed Pharmaceutical Co., Ltd. Transdermally absorptive preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EPSTEIN M S ET AL: "Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series", ORAL SURGERY, ORAL MEDICINE, ORAL PATHOLOGY, ORAL RADIOLOGY AND ENDODONTICS, MOSBY-YEAR BOOK, ST. LOUIS, MO, US, vol. 110, no. 5, 1 November 2010 (2010-11-01), pages 593 - 596, XP027399030, ISSN: 1079-2104, [retrieved on 20101016] *
JOSEPH GLIGOROV ET AL: "Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 112, no. 1, 20 December 2008 (2008-12-20), pages 53 - 66, XP019671209, ISSN: 1573-7217 *
SABRY M ATTIA ET AL: "Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 64, no. 4, 30 January 2009 (2009-01-30), pages 837 - 845, XP019738510, ISSN: 1432-0843, DOI: 10.1007/S00280-009-0934-8 *

Also Published As

Publication number Publication date
WO2012069150A2 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
WO2012027065A3 (en) Combination therapy for treatment of disease
WO2011041729A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
WO2010111640A3 (en) Anti-influenza formulations and methods
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
UA95644C2 (en) Pyridizinone derivative, pharmaceutical composition and treatment method
AU2016219643A1 (en) Pharmaceutical combination for the treatment of pain
WO2010077883A3 (en) Antagonists of lysophosphatidic acid receptors
WO2014002051A3 (en) Complement pathway modulators and uses thereof
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2011041462A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2010037059A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2014002058A3 (en) Complement pathway modulators and uses thereof
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2011028044A3 (en) Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
WO2011028043A3 (en) Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
ZA201101278B (en) Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2011023367A3 (en) Bisphosphonate-prodrugs
ZA201203281B (en) Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11799627

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11799627

Country of ref document: EP

Kind code of ref document: A2